(XCEM) Columbia EM Core ex-China - Overview
Etf: Financials, Technology
Dividends
| Dividend Yield | 3.38% |
| Yield on Cost 5y | 4.36% |
| Yield CAGR 5y | 19.33% |
| Payout Consistency | 78.4% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 17.1% |
| Relative Tail Risk | 1.81% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.07 |
| Alpha | 34.19 |
| Character TTM | |
|---|---|
| Beta | 0.688 |
| Beta Downside | 0.685 |
| Drawdowns 3y | |
|---|---|
| Max DD | 18.92% |
| CAGR/Max DD | 1.02 |
Description: XCEM Columbia EM Core ex-China January 19, 2026
The Columbia EM Core ex-China ETF (NYSE ARCA: XCEM) commits at least 80 % of its net assets to the constituents of its benchmark index and typically holds about 95 % of assets in those securities, making it a highly concentrated, non-diversified vehicle focused on emerging-market equities that exclude China.
In practice, the fund’s sector tilt is dominated by financials and information-technology stocks, which together accounted for roughly 55 % of the index weightings in the most recent quarterly report (Q3 2024). Recent data shows Chinese-listed banks and fintech firms have been pressured by tighter credit conditions and regulatory scrutiny, while the broader Asia-Pacific IT sector is benefiting from accelerated 5G roll-outs and cloud-infrastructure spending, driving an average year-over-year revenue growth of about 12 % across the top holdings. The ETF’s expense ratio sits at 0.68 % and its assets under management are estimated at $420 million, implying modest liquidity but sufficient scale for institutional participation.
If you want a deeper, data-driven view of XCEM’s risk-return profile and how its sector exposures compare to peers, a quick look at ValueRay’s analytics can help you spot any hidden concentration risks.
What is the price of XCEM shares?
Over the past week, the price has changed by +1.78%, over one month by +7.82%, over three months by +14.94% and over the past year by +46.29%.
Is XCEM a buy, sell or hold?
What are the forecasts/targets for the XCEM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 51.6 | 20.4% |
XCEM Fundamental Data Overview February 09, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.51b USD (1.51b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.51b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.51b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.45% (E(1.51b)/V(1.51b) * Re(8.45%) + (debt-free company))
Discount Rate = 8.45% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)